Aldeyra Therapeutics, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -28.1% | -26.1% | -24.8% |
| FY2022 | -41.1% | -37.4% | -34.2% |
| FY2023 | -31.3% | -31.3% | -25.3% |
| FY2024 | -78.7% | -64.9% | -53.4% |
| FY2025 | -76.5% | -76.5% | -47.0% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -28.1% | -26.1% | -24.8% |
| FY2022 | -41.1% | -37.4% | -34.2% |
| FY2023 | -31.3% | -31.3% | -25.3% |
| FY2024 | -78.7% | -64.9% | -53.4% |
| FY2025 | -76.5% | -76.5% | -47.0% |